Generate a tailored SOP for Dr. Peter Van Galen. Improve your application with a focused, well-structured draft.
Dr. van Galen studies normal and malignant hematopoiesis with a focus on hematopoietic stem cell aging, development, and acute myeloid leukemia. His projects span age-associated inflammatory pathways, targeted therapies for leukemia, and anti-tumor immunity. He employs innovative experimental and computational tools, including single-cell sequencing and bioinformatics, to analyze blood cells at genetic, transcriptional, and epigenetic levels. Dr. van Galen's aim is to translate a deeper understanding of blood cell biology into new therapies to improve human health. He received his Bachelor of Science in Biology and Master of Science in Cancer Genomics and Developmental Biology from Utrecht University in the Netherlands. In 2009, he joined the laboratory of Dr. John Dick at the University of Toronto, co-supervised by Dr. Maarten van Lohuizen at the University of Amsterdam, where he studied the transcriptional regulation of stress pathways in hematopoiesis. He graduated cum laude with his thesis on "Molecular regulation of human hematopoietic stem cells." In 2014, Dr. van Galen joined the laboratory of Dr. Bradley Bernstein at Massachusetts General Hospital and the Broad Institute of MIT and Harvard in Boston, developing technologies to uncover the epigenetic, transcriptional, and genetic features of acute myeloid leukemia cells. In 2019, he became a member of the Hematology Division at Brigham Women’s Hospital, Department of Medicine of Harvard Medical School, where he established his laboratory.
Brigham Women's Hospital, Harvard Medical School • Boston, MA
Starting a laboratory focusing on hematopoiesis and leukemia.
Administered by the Division of Medical Sciences (DMS). GRE is not required and will not be considered for BBS, Immunology, and Neuroscience.